Across TCGA pan-cancer cohorts, C6orf47 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C6orf47 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C6orf47 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C6orf47 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where C6orf47 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.558	0.205	.010	20	view →
CCRCC	OS	Median	II,III,IV	0.854	0.613	.016	9	view →
LUAD	DFS	Quartile	All	0.758	1.000	.034	2	view →
LSCC	OS	Median	All	0.879	0.741	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: C6orf47 tumor-vs-normal RNA expression · all C6orf47 data types